comparison between propensity-score matched cohorts during 12-month follow-up time period Semadlutide Non-GI P-1RAs

Incident CUD diagnosis in patients with type 2 diabetes and no prior history of CUD

	cohort	11011 021 111/10		
Population		anti-diabetes medications cohort	HR (95% CI)	
Overall (n = 25,820/cohort)	0.21% (54)	0.48% (123)	-	0.40 (0.29–0.56)
Women (n = 17,776/cohort)	0.21% (25)	0.34% (40)	-	0.58 (0.35–0.95)

Men (n = 12,174/cohort) 0.22% (27) 0.46% (56)

age \leq 55 years (n = 9,997/cohort) 0.36% (36) 0.54% (54) 0.12% (20) 0.33% (53) 0.34% (13) 0.60% (23)

0.44(0.28-0.69)0.61 (0.40-0.93) 0.35 (0.21–0.58) 0.52(0.27-1.03)0.22% (34) 0.33% (52) 0.19% (19) 0.35% (36)

age > 55 years (n = 16,089/cohort) Black (n = 3.842/cohort) White (n = 15,712/cohort)No obesity (n = 10,195/cohort)

0.60(0.39 - 0.93)0.47(0.27-0.82)0.46(0.31 - 0.69)Obesity (n = 15,609/cohort) 0.22% (34) 0.44% (69) -0.10 0.20 0.40 0.80 2.0 4.0 8.00

Hazard Ratio (HR)